It marks the second COVID-19 vaccine approved for public use in China, after a shot developed by a Beijing institute affiliated to state-owned China National Pharmaceutical Group (Sinopharm) was approved in December. Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay, and Laos have granted emergency authorisation for the CoronaVac vaccine developed by Sinovac Life Sciences, Sinovac said in a news release. It is expanding its capacity to fill vaccine into vials and syringes, which currently lags its vaccine manufacturing capacity. The success rate from the Turkey trial was 91.25%, local researchers said, based on a preliminary analysis of 29 cases. The Brazil trial also found the vaccine was 83.7% effective against the disease that requires medical treatment, and 100% effective against hospitalization, severe cases and death in the same trial, Sinovac said on Friday.

Source: bd News24 February 06, 2021 10:30 UTC